Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Maze Therapeutics, Inc.NASDAQ: MAZE
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses dips below year-ago levels
Q1 FY2026 other income / expenses of $2.35M fell 10.3% year over year, behind the +295.2% change in trailing-twelve-month other income / expenses. Sequentially, it fell 32.8% from the prior quarter.
Context
- Other income / expenses increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -10.3% toward the trailing-twelve-month pace of +295.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 11.78M USD
- Year-over-year change
- +381.6%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.78M | +381.6% |
| FY2024 | 2024-12-31 | (4.18M) | -124.4% |
| FY2023 | 2023-12-31 | (1.86M) | +52.4% |
| FY2022 | 2022-12-31 | (3.91M) | — |
Other Income / Expenses vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +295.2% is the highest of 8, against a peer median of -56.2%.
- Other income / expenses amounts to 57.5% of revenue for MAZE, versus a peer median of 19.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
SEPNSepterna, Inc. | LTM Sep 2026 | $20.33M USD | +12.8% | — | 21.1% |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $11.78M USD | +9.2% | +266.7% | 114.2% |
| LTM Mar 2026 | $11.51M USD | +295.2% | — | 57.5% | |
| LTM Mar 2026 | $1.66M USD | -21.3% | +67.5% | — | |
| LTM Mar 2026 | -$20.52M USD | -56.2% | — | 4.8% | |
| LTM Sep 2026 | -$26.23M USD | -1115.7% | — | 4.0% | |
| LTM Jun 2026 | -$183.33M USD | -250.6% | — | 18.2% | |
| FY2025 | -€211.38M EUR | -144.8% | — | 4715.1% | |
| Peer median (excluding MAZE) | — | -56.2% | +167.1% | 19.6% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 167.5M | 0 |
| Cost of Revenue | 0 | 0 | 0 | 2.4M |
| Gross Profit | 0 | 0 | 167.5M | (2.4M) |
| Gross Margin | — | — | 100.0% | — |
| Research & Development | 88.19M | 73.95M | 83.5M | 108.45M |
| Selling, General & Admin | 22.83M | 24.61M | 26.42M | 34.45M |
| Operating Expenses | 111.03M | 98.55M | 109.91M | 140.5M |
| Depreciation & Amortization | 3.82M | 4.09M | 3.3M | 2.4M |
| EBITDA | (111.12M) | (96.33M) | 56.7M | (128.72M) |
| EBITDA Margin | — | — | 33.9% | — |
| Operating Income | (111.03M) | (98.55M) | 57.59M | (142.9M) |
| Operating Margin | — | — | 34.4% | — |
| Interest Income | 2.03M | 1.97M | 4.65M | 11.78M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (3.91M) | (1.86M) | (4.18M) | 11.78M |
| Income Before Tax | (114.94M) | (100.42M) | 53.4M | (131.12M) |
| Pre-Tax Margin | — | — | 31.9% | — |
| Income Tax Expense | 0 | 0 | 1.17M | 0 |
| Net Income | (114.94M) | (100.42M) | 52.23M | (131.12M) |
| Net Margin | — | — | 31.2% | — |
| EPS (Basic) | (2.63) | (2.29) | 0.08 | (3.05) |
| EPS (Diluted) | (2.63) | (2.29) | 0.08 | (3.05) |
| Weighted Avg Shares | 43.78M | 43.78M | 43.8M | 42.98M |
| Weighted Avg Shares (Diluted) | 43.78M | 43.78M | 43.8M | 42.98M |
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.